ReviewJournal of thoracic disease2017
Lung neuroendocrine tumors: pathological characteristics.
Review in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Three-Tier Prognostic Stratification of Lung Carcinoids (NET G1-G2-G3) by Multivariable, Data-Driven Integration of Ki-67 and Mitotic Count.Endocrine pathology · 2026Article
- Small cell lung carcinoma metastatic to the stomach: Commonly overlooked, limited treatment options.World journal of gastroenterology · 2024Article
- Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma.Journal of thoracic disease · 2023Article
- Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma.Journal of clinical medicine · 2022Article
- Article
- Hierarchical identification of a transcriptional panel for the histological diagnosis of lung neuroendocrine tumors.Frontiers in genetics · 2022Article
- Unravelling actionable biology using transcriptomic data to integrate mitotic index and Ki-67 in the management of lung neuroendocrine tumors.Oncotarget · 2021Article
- Incidence, treatment, and survival analysis in esophageal neuroendocrine carcinoma population.Translational cancer research · 2020Article
- Epithelial-Mesenchymal Transition Proteins in Neuroendocrine Neoplasms: Differential Immunohistochemical Expression in Different Sites and Correlation with Clinico-Pathological Features.Diagnostics (Basel, Switzerland) · 2020Article
- Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection.Journal of clinical medicine · 2020Article
- Comparative study of large cell neuroendocrine carcinoma and small cell lung carcinoma in high-grade neuroendocrine tumors of the lung: a large population-based study.Journal of Cancer · 2019Article
- Clinicopathological and immunohistochemical study of pulmonary neuroendocrine tumors - A single-institute experience.Lung India : official organ of Indian Chest SocietyArticle
- Growth Rates of Pulmonary Carcinoid Tumors and Hamartomas.Journal of computer assisted tomographyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms comprising four histologic types, namely typical and atypical carcinoid (TC and AC), large-cell neuroendocrine and small cell carcinoma (SCC). Classification criteria include the number of mitoses per 2 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.